Sodium derangements occur relatively frequently in patients admitted to ICUs and can cause direct injury as cells are exposed to hypertonic or hypotonic stress, associated with an increased risk of morbidity or even death ([@R1], [@R2]). Accurate and rapid plasma sodium measurements are essential to guide therapeutic decisions. Under- or overestimating sodium can cause harm, especially since the treatment of either condition is often directly opposing (and if in error, exacerbating) the alternate condition. Consequentially, sodium measurements have long been a central focus in clinical laboratory medicine throughout its history. These began with time-consuming zinc uranyl acetate precipitation in the 1920s ([@R3]). Sodium measurements were much accelerated with the introduction of flame photometers in the 1940s ([@R4], [@R5]). Flame photometry was eventually replaced by ion-selective electrode (ISE)-based measurements, which are more accurate and less interference-prone to blood lipids and proteins ([@R6]). Today, ISE measurements are widely used in clinical practice and are the standard of care. Clinicians have learned to rely on ISE measurements; however, even with modern ISE technology, there is still a potential for interference from biological components and drugs ([@R7]), which is important to recognize.

In this report, we show that vecuronium bromide and esmolol hydrochloric acid (HCl), two drugs commonly used in critical care for muscle relaxation and to lower blood pressure/reduce arrhythmia, respectively, were noted to be associated with pseudohypernatremia in ICU patients. Neither drug is known to be associated with ISE interference, but both caused pseudohypernatremia in plasma samples measured by the Vitros 5600 chemistry analyzer (Ortho Clinical Diagnostics, Raritan, NJ). We conducted laboratory experiments reproducing the pseudohypernatremia in vitro and performed an analysis from our electronic medical record to further define the scope of the problem. The possibility of drug-ISE interference may not be immediately obvious but it is important for clinicians to be aware of this possible finding as it has the potential to lead to inappropriate interventions in patients with falsely elevated sodium concentrations.

MATERIALS AND METHODS
=====================

Human Subjects
--------------

We retrieved the electronic medical records of patients admitted to Children's Hospital of Philadelphia between 2016 and 2018 who received either esmolol HCl or vecuronium bromide during their hospitalization. Our electronic medical record review was approved by the Institutional Review Board (IRB) of the Children's Hospital of Philadelphia, which waived the need for informed consent (IRB 18-015908).

Sodium Measurements
-------------------

Basic metabolic panel (BMP) sodium measurements were performed on a Vitros 5600 or Vitros 4600 chemistry analyzer, as well as a Beckman Coulter AU 5822 (Beckman Coulter, Brea, CA). Blood gas (BG) sodium measurements were obtained on Siemens RAPIDLab 1265 BG analyzers (Siemens, Tarrytown, NY) in the central laboratory and by iSTAT (Abbott Point of Care, Abbott, Lake Bluff, IL) at the bedside, using the manufacturer's reagents and parameters.

In Vitro Drug Spiking to Assess for Pseudohypernatremia
-------------------------------------------------------

We pooled surplus deidentified plasma samples and obtained a baseline sodium measurement. We added esmolol HCl, vecuronium bromide, nicardipine HCl, labetalol HCl, or cisatracurium besilate to separate plasma pools and used different instruments to measure the sodium concentrations. We calculated expected sodium values using the known dilution factors and baseline sodium measurement of the pooled plasma samples. The Nicardipine HCl vial contained 75 mg sodium chloride in 10 mL (Na 128.3 mmol/L), and esmolol HCl was prepared in 0.9% normal saline (Na 154 mmol/L). These concentrations were factored into the expected sodium calculations.

Data Analysis
-------------

Data were analyzed using Microsoft Excel 16.24 (Microsoft, Redmond, WA), SAS 9.4 with SAS/STAT 15.1 (SAS Institute, Cary, NC), and GraphPad Prism 8.2 (GraphPad Software, San Diego, CA). Electronic medical record data included sodium measurements by BMP or BG, as well as vecuronium and esmolol infusions. We included only continuous infusions with weight-based dosing data into our analysis so that we could map infusion intervals with sodium measurements and adjust for patient size. For the multivariate analysis (Fig. [4](#F4){ref-type="fig"}), we used normally distributed generalized estimating equations (GEEs) with compound symmetry covariance that was estimated using the maximum likelihood estimator and empirical [se]{.smallcaps}s ([@R8], [@R9]) to predict the Δ sodium (BMP--BG) following within 12 hours of a vecuronium and/or esmolol dose. We determined Δ sodium by identifying BMP sodium measurements and ascertaining if BG sodium measurements occurred ± 12 hours before or after the BMP measurement. The closest BG measurement was taken to calculate the Δ sodium (BMP--BG). Next, we identified if the Δ sodium (BMP--BG) occurred within 12 hours after a vecuronium and/or esmolol dose. If multiple doses occurred, averages (means) were calculated. Sensitivity analyses were also conducted to confirm the results were maintained with adjustments for differences in time between drug and sodium measurements. For the analysis in Figure [5](#F5){ref-type="fig"}, we normalized data by calculating averages of sodium measurements (BMP, BG) as well as average vecuronium bromide and/or esmolol infusion rates for each patient per day of admission. Data were tested for normal distribution using D'Agostino and Pearson testing. We used Spearman correlation to compare sodium measurements with vecuronium or esmolol doses. We determined dose-response curve associations through regression analysis. Data were displayed as mean ± [sem]{.smallcaps} or mean with 95% CI.

RESULTS
=======

Initial Observations of Vecuronium- and Esmolol-Induced Pseudohypernatremia
---------------------------------------------------------------------------

An infant with autosomal recessive polycystic kidney disease received continuous renal replacement therapy (CRRT). Although on CRRT, laboratory studies became notable for rising sodium levels on routine BMP. Enteral feeding regimen had remained stable on fortified formula, the infant received no sodium chloride supplementation, and all CRRT bags had standard sodium concentration of 140 mmol/L. Medications included sildenafil, treprostinil, vecuronium, ketamine, and norepinephrine. Interestingly, there was significant discrepancy between the sodium levels on BGs (RAPIDLab 1265; Siemens, Tarrytown, NY) and BMP chemistries (Vitros 5600 Integrated Systems; Ortho Clinical Diagnostics, Raritan, NJ), with the BG results consistent with normonatremia. Of note, increasing vecuronium bromide infusion rate coincided with the patient's rising BMP sodium measurements (**Fig. [1](#F1){ref-type="fig"}*A***), raising suspicions that the BMP sodium may be due to a drug interference with the sodium measurement. To further investigate if vecuronium caused BMP sodium measurement interference, we obtained blood samples from the sample patient pre- and post-dialysis filter. Vecuronium is water-soluble and small enough (without bromide: 557.84 g/mol) to be removed during CRRT. Post-filter sodium corrected back down to BG sodium measurements, below the dialysate sodium concentration, which could not be explained with genuine hypernatremia (**Fig. [1](#F1){ref-type="fig"}*B***). We made similar observations in a second patient where the BMP sodium measurements returned to the BG baseline as soon as vecuronium therapy was discontinued (**Fig. [1](#F1){ref-type="fig"}*C***). In a third patient on high-dose vecuronium bromide infusion (2.5 mg/kg/hr), we noticed a simultaneous BMP and BG sodium of 192 and 134 mmol/L from the central line, respectively, while a capillary BMP sodium was 135 mmol/L. In addition to vecuronium, we have also observed that esmolol HCl is capable of inducing a similar discrepancy between BMP and BG sodium measurements ([@R10]), with the esmolol infusion rate increasing measured BMP sodium (**Fig. [1](#F1){ref-type="fig"}*D***). Together, these observations led to the hypothesis that vecuronium bromide and esmolol HCl may interfere with BMP measurements and cause pseudohypernatremia.

![Vecuronium and esmolol related pseudohypernatremia. Observations of pseudohypernatremia in three individual patients associated with vecuronium bromide (case 1: **A**, **B**; case 2: **C**) and esmolol hydrochloric acid (**D**). Vitros 5600 analyzer basic metabolic panel (BMP) sodium from plasma samples showed prominent hypernatremia during vecuronium and esmolol infusions, which was absent on the blood gas (BG) analyzer, as well as on post-dialysis filter samples.](cc9-2-e0073-g001){#F1}

Pseudohypernatremia Can Be Replicated in Plasma Samples by Adding Vecuronium and Esmolol
----------------------------------------------------------------------------------------

To experimentally assess if vecuronium bromide and esmolol HCl can cause pesudohypernatremia, we added each medication separately to pooled plasma samples. We compared plasma BG (1265 RAPIDLab) and BMP measurements with the Vitros 5600, as well as a Beckman Coulter AU 5822 from the clinical laboratory at the Hospital of the University of Pennsylvania. We observed that both drugs affected BMP sodium measurements from the Vitros chemistry analyzer in a dose-dependent manner (**Fig. [2](#F2){ref-type="fig"}*A***--***C***). We conducted additional drug-spiking experiments with other common ICU drugs: the calcium channel blocker nicardipine (**Fig. [2](#F2){ref-type="fig"}*D***), as well as the vecuronium and esmolol drug class relatives, cisatracurium, and labetalol (**Fig. [2](#F2){ref-type="fig"}**, ***E*** and ***F***). We did not observe such findings with nicardipine (Fig. [2](#F2){ref-type="fig"}*D*). Cisatracurium and labetalol did produce an increase in BMP sodium measurements, although only at higher doses (Fig. [2](#F2){ref-type="fig"}, *E* and *F*). Taken together, the drug-induced increase in sodium measurements suggested some form of drug interference with the ISE used in the Vitros chemistry instruments.

![Vecuronium and esmolol added to plasma replicate pseudohypernatremia. Esmolol hydrochloric acid (**A**) and vecuronium bromide (**B**) were added to pooled plasma samples. Basic metabolic panel (BMP) sodium was measured by the Vitros 5600, Vitros 4600, and Beckman Coulter AU 5822 (AU). Blood gas (BG) sodium was measured by the 1265 RAPIDLab BG analyzer. The expected sodium is calculated based upon the baseline sodium measurement in the plasma pool without added drug, and the dilution factor of the esmolol or vecuronium in the plasma mixture. The *shaded area* indicates measurements where the absolute sodium concentration was greater than 250 mmol/L, likely underestimating the amount of pseudohypernatremia. **C**, Linear regression of absolute sodium measurements and drug concentrations show that both vecuronium and esmolol increased sodium measurements in a dose-dependent manner. Negative controls using nicardipine (**D**), cisatracurium (**E**), and labetalol (**F**). *Arrows* indicate 10% increase in BMP sodium measurements in vecuronium and esmolol (*red*), as well as cisatracurium and labetalol (*purple*). Data were obtained on two independent devices and displayed as mean ± [sem]{.smallcaps}.](cc9-2-e0073-g002){#F2}

Vecuronium and Esmolol Chemical Structures Do Not Reveal Overt Cause of ISE Interference
----------------------------------------------------------------------------------------

Drugs can alter ISE-based measurements by forming complexes with the ionophore, binding electrolytes of interest, or by changing the behavior of the ion-selective membrane ([@R7], [@R11]). Benzalkonium is known to interfere with the Vitros sodium ISE ([@R12]). The structure of benzalkonium is notable for a quaternary ammonium group (**Fig. [3](#F3){ref-type="fig"}*A***), a feature shared by vecuronium (**Fig. [3](#F3){ref-type="fig"}*B***), but not esmolol (**Fig. [3](#F3){ref-type="fig"}*C***). In fact, the molecules of esmolol and vecuronium are quite distinct in size and charge, and it is difficult to speculate how a similar effect can be reproducibly achieved by both drugs. One common feature shared by both drugs is the presence of "acetoxy" groups, CH~3~-C(=O)-O-, with esmolol and vecuronium having one and two each, respectively, and vecuronium appearing to have stronger effects at equal doses (Fig. [2](#F2){ref-type="fig"}*C*). However, two of our three negative controls also have acetoxy-groups and one quaternary ammonium group (**Fig. [3](#F3){ref-type="fig"}*D***--***F***). These inconsistent observations make it difficult to speculate on the mechanisms of vecuronium and esmolol mediated sodium ISE interference on the Vitros.

![Structural formulas of drugs evaluated for sodium ion-selective electrode (ISE)-interference. Structural formulas of benzalkonium (**A**), vecuronium (**B**), esmolol (**C**), labetalol (**D**), nicardipine (**E**), and cisatracurium (**F**).](cc9-2-e0073-g003){#F3}

Vecuronium Is Associated With BMP--BG Sodium Discrepancies in a Dose-Dependent Manner
-------------------------------------------------------------------------------------

Vecuronium and esmolol are medications frequently used in the ICU. The incidental clinical observations and subsequent experimental validation of drug-induced pseudohypernatremia made us question how common BMP (pseudo)hypernatremia occurred in our institution in patients on vecuronium or esmolol infusions. We systematically queried our electronic medical records and retrieved patient sodium measurements (BMP, BG) from all patients admitted to Children's Hospital of Philadelphia from 2016 to 2018 who received vecuronium and/or esmolol treatment during their admissions. The BG sodium values include measurements made by point-of-care testing at the bedside (iSTAT), in addition to the central laboratory instruments (RAPIDLab 1265). We analyzed our data using multivariate analysis and a GEE. We determined the Δ sodium (BMP--BG) up to 12 hours between the two sodium measurements. Drug dosages were associated with a Δ sodium if the sodium measurements occurred within a 12-hour period after a dose of vecuronium or esmolol, recorded as mg/kg/hr or μg/kg/min, respectively. This resulted in 6,938 time points of sodium measurements from 747 patients. We found that the mean vecuronium dose could predict the increase in BMP over BG sodium measurements (**Fig. [4](#F4){ref-type="fig"}**, ***A*** and ***B***). We observed a similar trend for esmolol (**Fig. [4](#F4){ref-type="fig"}**, ***C*** and ***D***), although not statistically significant, perhaps due to a lower number of patients receiving esmolol (252 receiving vecuronium vs 33 receiving esmolol) and fewer available observations (564 vs 127). To further examine a link between BMP pseudohypernatremia and vecuronium or esmolol administration, we generated dose-response curves (**Fig. [5](#F5){ref-type="fig"}*A***) similar to our vecuronium/esmolol and plasma mixing studies (Fig. [2](#F2){ref-type="fig"}*C*). We consolidated our data by forming average sodium levels and drug doses per patient per day, which led to 3,469, 533, and 27 patient days with documented vecuronium, esmolol or both drugs with recorded weight-specific dosing rates, respectively. Although the curve fitting was far less optimal than in our equivalent in vitro studies (Fig. [2](#F2){ref-type="fig"}*C*), it is remarkable how closely both curves overlap, thus highlighting the relative difference between vecuronium and esmolol and their effect on BMP sodium measurements (**Fig. [5](#F5){ref-type="fig"}*B***).

![Electronic medical record review supports drug-induced pseudohypernatremia. Electronic medical records of Children's Hospital of Philadelphia were systematically queried for patients receiving esmolol and/or vecuronium at some point during their hospital stay(s) during 2016--2018. **A** and **B**, Show data on vecuronium and (**C**, **D**) esmolol. **A** and **C**, Shows a histogram of non-zero values of mean drug doses using the Terrel and Scott algorithm ([@R9]). **B** and **C**, Shows the predicted Δ sodium (BMP--BG) within ± 12 hr after vecuronium or esmolol administration up to 12 hr. The predicted Δ sodium (BMP--BG) is plotted as *solid line* and calculated from using normally distributed generalized estimating equations with compound symmetry covariance that was estimated using the maximum likelihood estimator. The *dashed lines* and *gray areas* indicate 95% CIs of the predicted Δ sodium (BMP--BG) using empirical [se]{.smallcaps}s. \*\* and \*\*\*indicate *p* \< 0.01 and *p* \< 0.001, respectively. BG = blood gas, BMP = basic metabolic panel.](cc9-2-e0073-g004){#F4}

![Dose-response curves of vecuronium and esmolol on basic metabolic panel (BMP) sodium. **A**, Vitros 5600 sodium measurements from patients in Figure [4](#F4){ref-type="fig"} matched with esmolol or vecuronium treatment doses (normalized to mg/kg/hr). *Solid lines* indicate plotted regression curves. *Dashed lines* indicate 95% CIs of the best fit line. **B**, Overlay of fitted curves from Figure [5](#F5){ref-type="fig"}*A* and Figure [2](#F2){ref-type="fig"}*C*, showing a similar relationship between esmolol and vecuronium exposure and Vitros 5600 sodium measurements in vitro when drugs were added to plasma (right *y*-axis, lower *x*-axis) and in vivo, from patients treated with vecuronium or esmolol (left *y*-axis, upper *x*-axis).](cc9-2-e0073-g005){#F5}

In conclusion, our clinical data show that vecuronium and esmolol dosing can affect BMP sodium measurements on Vitros instruments. Together with our in vitro studies and earlier clinical observations, these findings are consistent with vecuronium and esmolol causing drug-induced interference with BMP-sodium measurements on Vitros chemistry systems.

DISCUSSION
==========

The electrochemical measurement of sodium by ISE is the most common method used in clinical laboratories today and is considered to be the gold standard. ISEs are used in automated chemistry analyzers as well as BG and point-of-care instruments. ISE has replaced older methods for sodium measurement, such as atomic absorption spectroscopy and flame emission spectroscopy, both of which are impractical today in the modern clinical laboratory due to increased safety and maintenance requirements. ISE-based methodologies have excellent accuracy and precision, rapid turnaround time and high sample throughput, operate at a reasonably low cost, and use small amounts of blood. The latter is especially important in pediatric hospitals ([@R13], [@R14]), but is useful everywhere ([@R15]).

The selectivity of an ISE for a particular electrolyte is determined by the composition of the ion-selective membrane. Ion-selective membranes can be composed of glass, crystalline, or polymeric materials. In particular, sodium electrodes may contain either sodium-specific glass or polyvinyl chloride membranes with sodium-specific ionophores, such as methyl monensin or other monensin derivatives ([@R7]). Although these materials are all selective for sodium, the particular ISE used varies by instrument manufacturer. The two primary methodologies used to measure sodium in this report, Vitros BMP and Siemens BG, use different sodium ISEs; the Vitros contains methyl monensin, while the Siemens BG ISE contains glass. Notably, the Beckman AU that we used as a third sampler, which did not show elevated sodium measurements (Fig. [2](#F2){ref-type="fig"}*B*), contains a crown ether membrane sodium electrode. Our data demonstrate that the Vitros ISE is uniquely sensitive to these particular drug interferences, as demonstrated both in vitro and in vivo (Fig. [2](#F2){ref-type="fig"}*C* and Fig. [5](#F5){ref-type="fig"}*B*). Therefore, the BG sodium measurements were considered more accurate and were used for clinical decision-making in the context of vecuronium and esmolol drug-induced pseudohypernatremia. It is important to note that all models of Vitros chemistry analyzers use the same sodium ISE as the 5600 Integrated System.

Laboratory test interferences are not uncommon in the clinical laboratory. Specifically for electrolytes, known interferences include contamination from IV fluids and therapeutic compounds, surfactants (i.e., benzalkonium), and sample matrix (i.e., hyperlipidemia and hyperproteinemia) ([@R7]). Of these, benzalkonium chloride, an antimicrobial agent that may be present within catheters, is a known interferent for the Vitros sodium ISE ([@R16]). However, there is no benzalkonium present within the catheters used in our critical care units or in the materials used to disinfect them. In the critical care setting, the majority of patients have indwelling intravascular access devices. We believe that the pseudohypernatremia observed in this study is a result of contamination of the blood sample during collection from this device. Although it is impractical to avoid drawing blood samples from indwelling catheters, doing so during a continuous drug infusion increases the risk of contamination and possible interference. For the patients reported here, when samples were drawn from the central line versus a peripheral site (heel stick or venous phlebotomy) during the drug infusion, we found the pseudohypernatremia to be present only in the central line sample.

Electrolytes can be measured by either direct or indirect ISEs. Indirect ISEs are subject to pseudohyponatremia secondary to a solvent exclusion effect in the presence of increased lipids or proteins in the sample matrix ([@R17]). Vitros instruments, in addition to BG and point-of-care instruments, use direct ISE technology. Therefore, sodium measurements from the Vitros BMP and Siemens BG should both be accurate in the setting of hyperlipidemia or hyperproteinemia.

In conclusion, we identified vecuronium and esmolol as drugs with the potential to interfere with ISE-derived sodium measurements and cause pseudohypernatremia in Vitros chemistry systems. This issue may be underappreciated in clinical practice. Although we identified the Vitros sodium ISE to be the unique methodology susceptible to interference by these two drugs, it is important to note that the Vitros analyzer is particularly well suited to pediatric populations ([@R18]). This is due to small sample and dead space volume requirements, gold standard bilirubin testing, and excellent tolerance of the more common laboratory test interferences (hemolysis, lipemia, and icterus). In general, the use of an alternative method to measure sodium, such as a different chemistry platform or a BG analyzer, when a BMP value appears out of context from the clinical picture, as well as avoiding central line blood draws during constant drug infusions, may help identify and overcome drug-associated pseudohypernatremia.
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